Premium
The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm
Author(s) -
Marmouset Vincent,
Joris Magalie,
Merlusca Lavinia,
Beaumont Marie,
Charbonnier Amandine,
Marolleau JeanPierre,
Gruson Bérengère
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2671
Subject(s) - lenalidomide , bortezomib , regimen , dexamethasone , medicine , thalidomide , oncology , multiple myeloma , chemotherapy
We describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment). After five cycles of chemotherapy, we observed two complete responses and one clinical remission. Together with the encouraging literature data on the effects of lenalidomide and bortezomib on BPDCN cells, our results might prompt further investigations of this regimen's value in BPDCN.